NASDAQ:BEAT - BioTelemetry Stock Price, Price Target & More

$34.00 +0.40 (+1.19 %)
(As of 04/24/2018 10:06 AM ET)
Previous Close$33.60
Today's Range$33.60 - $34.00
52-Week Range$23.30 - $39.20
Volume6,990 shs
Average Volume385,938 shs
Market Capitalization$1.13 billion
P/E Ratio34.64
Dividend YieldN/A
Beta0.86

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Debt-to-Equity Ratio0.80%
Current Ratio1.77%
Quick Ratio1.66%

Price-To-Earnings

Trailing P/E Ratio34.64
Forward P/E Ratio26.77
P/E Growth1.7

Sales & Book Value

Annual Sales$286.78 million
Price / Sales3.88
Cash Flow$1.8438 per share
Price / Cash18.44
Book Value$7.70 per share
Price / Book4.42

Profitability

EPS (Most Recent Fiscal Year)$0.97
Net Income$-15,950,000.00
Net Margins-5.56%
Return on Equity14.54%
Return on Assets8.08%

Miscellaneous

Employees1,600
Outstanding Shares32,730,000

How to Become a New Pot Stock Millionaire

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) announced its earnings results on Thursday, February, 22nd. The medical research company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.08. The medical research company earned $91.70 million during the quarter, compared to the consensus estimate of $88.33 million. BioTelemetry had a negative net margin of 5.56% and a positive return on equity of 14.54%. The business's quarterly revenue was up 69.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 earnings per share. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

7 brokerages have issued 1-year target prices for BioTelemetry's stock. Their forecasts range from $37.00 to $50.00. On average, they expect BioTelemetry's stock price to reach $43.6667 in the next twelve months. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, Chief Exec. Officer, Pres and Director (Age 54)
  • Mrs. Heather C. Getz CPA, Chief Financial Officer and Exec. VP (Age 43)
  • Mr. Peter F. Ferola, Sr. VP of Corp. Devel., Gen. Counsel & Sec. (Age 49)
  • Mr. Fred Broadway III, Sr. VP of Sales and Marketing (Age 48)
  • Dr. Peter R. Kowey M.D., FACC, FACP, FACCP, FCP, Medical Director and Chairman of Medical Advisory Board

Has BioTelemetry been receiving favorable news coverage?

News headlines about BEAT stock have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioTelemetry earned a news sentiment score of 0.19 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 45.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $33.60.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.13 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (BEAT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTelemetry (NASDAQ:BEAT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for BioTelemetry in the last 12 months. Their average twelve-month price target is $43.6667, suggesting that the stock has a possible upside of 28.43%. The high price target for BEAT is $50.00 and the low price target for BEAT is $37.00. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.712.75
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.6667$43.6667$43.50$43.50
Price Target Upside: 28.43% upside32.12% upside70.09% upside47.71% upside

BioTelemetry (NASDAQ:BEAT) Consensus Price Target History

Price Target History for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Dougherty & CoReiterated RatingBuy -> Buy$40.00 -> $41.00LowView Rating Details
10/26/2017Raymond JamesInitiated CoverageOutperform$37.00N/AView Rating Details
10/23/2017SunTrust BanksInitiated CoverageBuy$41.00N/AView Rating Details
9/15/2017Off Wall StreetInitiated CoverageSellMediumView Rating Details
8/10/2017SidotiReiterated RatingBuy$42.00 -> $49.00LowView Rating Details
7/19/2017BenchmarkBoost Price TargetBuy -> Buy$38.00 -> $44.00LowView Rating Details
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 -> $50.00HighView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

BioTelemetry (NASDAQ:BEAT) Earnings History and Estimates Chart

Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ:BEAT) Earnings Estimates

2018 EPS Consensus Estimate: $1.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.22$0.24$0.23
Q2 20181$0.27$0.27$0.27
Q3 20181$0.28$0.28$0.28
Q4 20181$0.29$0.29$0.29
Q1 20191$0.30$0.30$0.30
Q2 20191$0.35$0.35$0.35
Q4 20191$0.40$0.40$0.40

BioTelemetry (NASDAQ BEAT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.24N/AView Earnings Details
2/22/2018Q4 2017$0.24$0.32$88.33 million$91.70 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.25$0.16$82.10 million$81.02 millionViewN/AView Earnings Details
8/8/2017Q2 2017$0.21$0.23$58.39 million$58.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.1430$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
4/22/2013Q1 2013($0.03)$32.42 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.05)($0.25)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.10)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.18)($0.13)ViewN/AView Earnings Details
2/17/2010Q4 2009($0.12)($0.24)ViewN/AView Earnings Details
11/6/2009Q3 2009$0.03($0.11)ViewN/AView Earnings Details
8/5/2009Q2 2009$0.05$0.06ViewN/AView Earnings Details
4/30/2009Q1 2009$0.05$0.04ViewN/AView Earnings Details
2/17/2009Q4 2008$0.15$0.16ViewN/AView Earnings Details
10/30/2008Q3 2008$0.10$0.11ViewN/AView Earnings Details
7/22/2008Q2 2008$0.07$0.08ViewN/AView Earnings Details
4/29/2008Q1 2008$0.02ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioTelemetry (NASDAQ:BEAT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioTelemetry (NASDAQ BEAT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 87.29%
Insider Trading History for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

BioTelemetry (NASDAQ BEAT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Fred BroadwayInsiderSell54,158$34.17$1,850,578.8664,880View SEC Filing  
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.1025,420View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.8523,172View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.7028,849View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.5037,568View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.1844,293View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81189,838View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.9630,989View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.6437,886View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.4642,500View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.9050,159View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20216,685View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.0028,847View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.7538,672View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.4065,536View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12287,045View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.5626,637View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.3652,379View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.9465,536View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55287,045View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.4026,637View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.5052,379View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.2565,536View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75287,045View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.0026,637View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.2561,756View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.7278,721View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98347,373View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.9835,177View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.4771,719View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.7493,091View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02413,117View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.9045,838View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.3276,491View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.3299,973View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60450,606View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.2450,944View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03103,888View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58120,945View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60546,559View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.3266,503View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55103,888View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39120,945View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36546,559View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.8666,503View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65103,888View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90120,945View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30546,559View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.6066,503View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.0068,501View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96125,819View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04568,857View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.6070,119View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00187,629View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00164,467View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTelemetry (NASDAQ BEAT) News Headlines

Source:
DateHeadline
BioTelemetry Inc (BEAT) to Post Q1 2018 Earnings of $0.24 Per Share, Dougherty & Co ForecastsBioTelemetry Inc (BEAT) to Post Q1 2018 Earnings of $0.24 Per Share, Dougherty & Co Forecasts
www.americanbankingnews.com - April 24 at 7:50 AM
BioTelemetry (BEAT) Scheduled to Post Earnings on TuesdayBioTelemetry (BEAT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:10 AM
Comparing Acadia Healthcare (ACHC) and BioTelemetry (BEAT)Comparing Acadia Healthcare (ACHC) and BioTelemetry (BEAT)
www.americanbankingnews.com - April 22 at 1:36 AM
Zacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 MillionZacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 Million
www.americanbankingnews.com - April 21 at 2:52 AM
Zacks: Analysts Expect BioTelemetry Inc (BEAT) Will Post Earnings of $0.27 Per ShareZacks: Analysts Expect BioTelemetry Inc (BEAT) Will Post Earnings of $0.27 Per Share
www.americanbankingnews.com - April 19 at 3:10 PM
BioTelemetry (BEAT) Upgraded by BidaskClub to "Buy"BioTelemetry (BEAT) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 17 at 10:29 AM
BioTelemetry (BEAT) Downgraded to Buy at BidaskClubBioTelemetry (BEAT) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 12:03 PM
BioTelemetry (BEAT) Now Covered by Analysts at Raymond James FinancialBioTelemetry (BEAT) Now Covered by Analysts at Raymond James Financial
www.americanbankingnews.com - April 4 at 7:30 PM
Head-To-Head Contrast: BioTelemetry (BEAT) and AAC (AAC)Head-To-Head Contrast: BioTelemetry (BEAT) and AAC (AAC)
www.americanbankingnews.com - April 4 at 3:21 PM
Head to Head Analysis: BioTelemetry (BEAT) vs. Hanger (HNGR)Head to Head Analysis: BioTelemetry (BEAT) vs. Hanger (HNGR)
www.americanbankingnews.com - April 4 at 3:21 PM
BioTelemetry, Inc. (BEAT) Receives Average Rating of "Hold" from AnalystsBioTelemetry, Inc. (BEAT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 1:47 PM
$91.55 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter$91.55 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter
www.americanbankingnews.com - April 4 at 2:32 AM
Contrasting Acadia Healthcare (ACHC) and BioTelemetry (BEAT)Contrasting Acadia Healthcare (ACHC) and BioTelemetry (BEAT)
www.americanbankingnews.com - April 3 at 11:52 PM
BioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per ShareBioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per Share
www.americanbankingnews.com - April 2 at 5:16 PM
BioTelemetry (BEAT) Upgraded to "Buy" by BidaskClubBioTelemetry (BEAT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
Edited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMTEdited Transcript of BEAT earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 26 at 5:28 PM
Commit To Buy BioTelemetry At $24, Earn 10.2% Annualized Using Options - NasdaqCommit To Buy BioTelemetry At $24, Earn 10.2% Annualized Using Options - Nasdaq
www.nasdaq.com - March 24 at 8:41 AM
BioTelemetry (BEAT) Downgraded to Hold at BidaskClubBioTelemetry (BEAT) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 23 at 11:20 PM
WellCare Health Plans (WCG) vs. BioTelemetry (BEAT) Critical ComparisonWellCare Health Plans (WCG) vs. BioTelemetry (BEAT) Critical Comparison
www.americanbankingnews.com - March 23 at 8:52 AM
BioTelemetry (BEAT) Lowered to C at TheStreetBioTelemetry (BEAT) Lowered to C at TheStreet
www.americanbankingnews.com - March 22 at 8:28 AM
What Analysts Recommend for Amedisys and Peers in March 2018What Analysts Recommend for Amedisys and Peers in March 2018
finance.yahoo.com - March 19 at 8:10 AM
SunTrust Banks Comments on BioTelemetry, Inc.s Q1 2019 Earnings (BEAT)SunTrust Banks Comments on BioTelemetry, Inc.'s Q1 2019 Earnings (BEAT)
www.americanbankingnews.com - March 19 at 6:46 AM
$91.40 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter$91.40 Million in Sales Expected for BioTelemetry, Inc. (BEAT) This Quarter
www.americanbankingnews.com - March 18 at 4:25 AM
This Mornings Technical Outlook on Medical Research Stocks -- Agilent Technologies, BioTelemetry, Accelerate ... - PR Newswire (press release)This Morning's Technical Outlook on Medical Research Stocks -- Agilent Technologies, BioTelemetry, Accelerate ... - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:08 AM
Fred Broadway Sells 54,158 Shares of BioTelemetry, Inc. (BEAT) StockFred Broadway Sells 54,158 Shares of BioTelemetry, Inc. (BEAT) Stock
www.americanbankingnews.com - March 14 at 7:11 PM
BioTelemetry (BEAT) Upgraded by BidaskClub to BuyBioTelemetry (BEAT) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 10 at 7:10 PM
BioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from BrokeragesBioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 3:25 PM
Exploring BioTelemetry’s SegmentsExploring BioTelemetry’s Segments
finance.yahoo.com - March 6 at 5:47 PM
A Look at BioTelemetry’s Financial PerformanceA Look at BioTelemetry’s Financial Performance
finance.yahoo.com - March 6 at 5:47 PM
Millrace Asset Group Inc. Buys 41,100 Shares of BioTelemetry, Inc. (BEAT)Millrace Asset Group Inc. Buys 41,100 Shares of BioTelemetry, Inc. (BEAT)
www.americanbankingnews.com - March 5 at 12:52 PM
BioTelemetry (BEAT) Downgraded by BidaskClubBioTelemetry (BEAT) Downgraded by BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM
BioTelemetry Breaks Below 200-Day Moving Average - Notable for BEAT - NasdaqBioTelemetry Breaks Below 200-Day Moving Average - Notable for BEAT - Nasdaq
www.nasdaq.com - March 2 at 8:06 AM
Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways ... - GlobeNewswire (press release)Analysis: Positioning to Benefit within Bluerock Residential Growth REIT, National Presto Industries, Healthways ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:06 AM
BioTelemetry, Inc. (BEAT) Expected to Post Quarterly Sales of $91.40 MillionBioTelemetry, Inc. (BEAT) Expected to Post Quarterly Sales of $91.40 Million
www.americanbankingnews.com - March 1 at 4:34 AM
Equities Analysts Issue Forecasts for BioTelemetry, Inc.s FY2020 Earnings (BEAT)Equities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2020 Earnings (BEAT)
www.americanbankingnews.com - February 28 at 4:30 PM
BioTelemetry, Inc. (BEAT) Forecasted to Post Q1 2018 Earnings of $0.30 Per ShareBioTelemetry, Inc. (BEAT) Forecasted to Post Q1 2018 Earnings of $0.30 Per Share
www.americanbankingnews.com - February 28 at 8:56 AM
Equities Analysts Issue Forecasts for BioTelemetry, Inc.s FY2019 Earnings (BEAT)Equities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2019 Earnings (BEAT)
www.americanbankingnews.com - February 27 at 3:02 PM
Cortina Asset Management LLC Raises Holdings in BioTelemetry, Inc. (BEAT)Cortina Asset Management LLC Raises Holdings in BioTelemetry, Inc. (BEAT)
www.americanbankingnews.com - February 27 at 1:40 PM
 Analysts Anticipate BioTelemetry, Inc. (BEAT) Will Announce Earnings of $0.21 Per Share Analysts Anticipate BioTelemetry, Inc. (BEAT) Will Announce Earnings of $0.21 Per Share
www.americanbankingnews.com - February 27 at 1:24 PM
BioTelemetry, Inc. Forecasted to Post FY2018 Earnings of $1.26 Per Share (BEAT)BioTelemetry, Inc. Forecasted to Post FY2018 Earnings of $1.26 Per Share (BEAT)
www.americanbankingnews.com - February 27 at 11:35 AM
BioTelemetry Inc (BEAT) Files 10-K for the Fiscal Year Ended on December 31, 2017BioTelemetry Inc (BEAT) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 8:08 AM
BioTelemetry, Inc. (BEAT) Shares Bought by Comerica BankBioTelemetry, Inc. (BEAT) Shares Bought by Comerica Bank
www.americanbankingnews.com - February 25 at 5:10 AM
BioTelemetry, Inc. (BEAT) Shares Bought by Columbia Partners L L C Investment ManagementBioTelemetry, Inc. (BEAT) Shares Bought by Columbia Partners L L C Investment Management
www.americanbankingnews.com - February 24 at 4:20 PM
BioTelemetry (BEAT) Price Target Increased to $41.00 by Analysts at Dougherty & CoBioTelemetry (BEAT) Price Target Increased to $41.00 by Analysts at Dougherty & Co
www.americanbankingnews.com - February 23 at 6:14 PM
BioTelemetrys (BEAT) CEO Joseph Capper on Q4 2017 Results - Earnings Call TranscriptBioTelemetry's (BEAT) CEO Joseph Capper on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 23 at 6:07 PM
BioTelemetry Q4 Earnings Preview - BenzingaBioTelemetry Q4 Earnings Preview - Benzinga
www.benzinga.com - February 23 at 8:09 AM
BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results ... - GlobeNewswire (press release)BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:09 AM
BioTelemetry reports 4Q lossBioTelemetry reports 4Q loss
finance.yahoo.com - February 23 at 8:09 AM
BioTelemetry (BEAT) Announces Quarterly  Earnings ResultsBioTelemetry (BEAT) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 9:32 PM
BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial ResultsBioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 22 at 5:44 PM

SEC Filings

BioTelemetry (NASDAQ:BEAT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioTelemetry (NASDAQ:BEAT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTelemetry (NASDAQ BEAT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.